MediciNova, Inc.
(NASDAQ : MNOV)

( )
MNOV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -9.58%52.180.0%$1505.17m
GILDGilead Sciences, Inc. 2.35%74.901.0%$1306.64m
REGNRegeneron Pharmaceuticals, Inc. -0.22%544.012.5%$730.03m
AMGNAmgen, Inc. 1.08%224.811.3%$647.12m
NVAXNovavax, Inc. -5.62%45.47102.0%$585.67m
VRTXVertex Pharmaceuticals, Inc. 4.51%278.511.9%$552.42m
BIIBBiogen, Inc. 1.89%301.461.6%$417.13m
ILMNIllumina, Inc. 2.66%363.823.5%$370.74m
SRNESorrento Therapeutics, Inc. -1.90%5.171.8%$307.02m
SGENSeattle Genetics, Inc. 0.82%152.976.1%$255.19m
ALXNAlexion Pharmaceuticals, Inc. 3.25%106.142.0%$228.77m
AAgilent Technologies, Inc. 0.02%86.151.6%$198.62m
BMRNBioMarin Pharmaceutical, Inc. 2.85%106.704.3%$183.60m
MGNXMacroGenics, Inc. -2.12%23.146.2%$175.53m
CODXCo-Diagnostics, Inc. -2.61%17.560.0%$174.27m

Company Profile

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.